Početna stranicaPRRUF • OTCMKTS
add
Immutep Ltd
Preth. zaklj. cijena
0,18 $
Godišnji raspon
0,17 $ - 0,28 $
Tržišna kapitalizacija
292,16 mil. USD
Prosječna količina
500,00
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
ASX
Vijesti s tržišta
Investor's Business Daily
prije 2 sata
Tech Futures Rise As AI Giant Eyes $1 Tril; Tesla Run Continues
0,00 %
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (AUD) | pro 2023.info | Godišnja promjena |
|---|---|---|
Prihod | 1,06 mil. | 25,23 % |
Operativni troškovi | 2,40 mil. | 16,20 % |
Neto dohodak | −10,61 mil. | −2,93 % |
Neto profitabilnost | −1,01 tis. | 17,80 % |
Zarada po dionici | — | — |
EBITDA | −11,10 mil. | −8,28 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (AUD) | pro 2023.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 103,73 mil. | 51,71 % |
Ukupna imovina | 123,79 mil. | 43,92 % |
Ukupne obveze | 8,15 mil. | −12,60 % |
Ukupni kapital | 115,64 mil. | — |
Dionice u optjecaju | 1,19 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,83 | — |
Povrat imovine | −23,35 % | — |
Povrat kapitala | −24,65 % | — |
Tok novca
Neto promjena novca
| (AUD) | pro 2023.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −10,61 mil. | −2,93 % |
Gotovina od poslovanja | −9,23 mil. | −54,83 % |
Gotovina iz ulaganja | −209,56 tis. | −607,90 % |
Gotovina iz financiranja | −215,93 tis. | −278,22 % |
Neto promjena novca | −9,84 mil. | −69,40 % |
Slobodan tok novca | −6,90 mil. | −2,37 % |
Više
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Glavni izvršni direktor
Osnovano
2001
Web-lokacija
Zaposlenici
19
